Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies downgrades Raspberry Pi 'pending visibility of recovery'

(Sharecast News) - Jefferies downgraded Raspberry Pi on Wednesday to 'hold' from 'buy' "pending visibility of recovery", but hiked the price target to 770p from 448p. The bank said DeepSeek's approach on low-cost AI training and inferencing should result in the faster proliferation of edge AI across industrial applications.

"Raspberry Pi is well positioned to benefit, with edge AI and semiconductor sales likely to become significant contributors over 3-5 years," it said.

However, it also said that near-term visibility is low as destocking persists and that it has cut its estimates.

Based on the lower units guidance, Jefferies cut its 2024 revenue estimate to $260mn from $282m. This takes its adjusted EBITDA estimate for 2024 to $36.3m, in line with the trading update guidance of at least $36mn.

"We regard 2025 as a transition year, before an acceleration in board sales into 2026," it said.

This results in the bank's sales forecast being dropped from $324m to $291mn and its adjusted EBITDA from $48.8m to $42.4mn.

"After a slight decline in sales in 2024 due to the inventory correction, this represents an acceleration back to 12% growth in 2025," it said.

"Based on new wins on CM5 and edge AI contributing from 2026, we model sales growth to accelerate to 17.3% and 18.4% in 2026/27 respectively."

At 0950 GMT, the shares were down 3.7% at 717.07p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.